Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers.
The purposes of this study were to test the pharmacokinetics and renal and otologic tolerances of a once-daily regimen of netilmicin and teicoplanin administered intramuscularly, alone or in combination (4.5 and 6 mg/kg, respectively), for 7 days in 30 healthy male volunteers. Teicoplanin induced only a mild increase in enzymuria. Nephrotoxicity was moderate and reversible with netilmicin; there was increased enzymuria and alteration in diluting ability, without significant changes in urinary beta 2-microglobulin levels, concentrating ability, and glomerular filtration rate. Ototoxicity was not detected in any of the subjects. Our results suggest that (1) teicoplanin and netilmicin given once daily induced only slight, reversible tubular damage, without any sign of ototoxicity; (2) their combination was not more toxic; and (3) clinical studies can be envisaged to evaluate the efficacy and tolerance of once-daily regimens in long-term treatment.
Pierre
C
C
Institut National de la Santé et de la Recherche Médicale U 13, Hôpitaux Bichat et Claude Bernard, Université, Paris VII, France.
Blanchet
F
F
Seta
N
N
Chaigne
P
P
Labarre
C
C
Sterkers
O
O
Amiel
C
C
Carbon
C
C
D000118:Acetylglucosaminidase / Q000652:urine; D000328:Adult; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D004423:Ear / Q000187:drug effects; D006020:Glycopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007668:Kidney / Q000187:drug effects; D009428:Netilmicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D017334:Teicoplanin
D006020:Glycopeptides; D009428:Netilmicin; D017334:Teicoplanin; D000118:Acetylglucosaminidase